Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Secondary Progressive Multiple Sclerosis (SPMS) Disease Overview, Epidemiology and Drug Overview 2017-2024 - Research and Markets

Research and Markets
Posted on: 05 Dec 17

The "Secondary Progressive Multiple Sclerosis (SPMS) - Disease Overview, Epidemiology and Drug Overview" report has been added to Research and Markets' offering.

The report provides an overview of secondary progressive multiple sclerosis (SPMS) disease indication in detail, highlights the SPMS epidemiology in the present scenario and includes forecasts in key geographies across the globe. The report elaborates on the drugs prescribed and expected to be prescribed in SPMS by physicians.

The report starts with the basic definition, causes and symptoms of Multiple Sclerosis (MS) and further details the types of Multiple Sclerosis disease indication. The report elaborates on the Secondary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of a SPMS patient, symptoms of a SPMS patient, and disease progression in a SPMS patient. The report further highlights the multiple methods through which the patient can be diagnosed for SPMS.

The middle part of the report consists of SPMS epidemiology and prevalence in the key geographies across the globe such as the US, UK, Germany, Italy, France, Spain and Japan. The epidemiology for SPMS indication across key geographies has been forecasted up to 2024.

The latter part of the report highlights the importance of factors influencing physician prescription decisions in SPMS such as efficacy factors, tolerability factors, monitoring requirements and pricing factors. The report further details the drugs prescribed or expected to be prescribed in SPMS by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of drug in the SPMS market.

Key Topics Covered:

1. Multiple Sclerosis Definition

2. Types of Multiple Sclerosis

3. Secondary Progressive Relapsing MS Defined

4. Causes of SPMS

5. Profile of SPMS Patient

6. Symptoms of SPMS

7. Disease progression and impact on QoL

8. Disease Diagnosis

9. Disease Epidemiology

10. Factors impacting a physician's prescription decision

11. Disease Modifying Therapies for SPMS

For more information about this report visit https://www.researchandmarkets.com/research/crj539/secondary

View source version on businesswire.com: http://www.businesswire.com/news/home/20171205006188/en/

Business Wire
www.businesswire.com

Last updated on: 05/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.